Gut microbiota and sirtuins in obesity-related inflammation and bowel dysfunction

Journal of Translational Medicine

Volumn 9, Issue 1, 2011, Pages

  Lakhan, Shaheen E ^a   Kirchgessner, Annette ^a,b  

^a Global Neuroscience Initiative Foundation   (United States)

^b SETON HALL UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AVOPARCIN; BACTERIUM LIPOPOLYSACCHARIDE; GENTAMICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; RIFAXIMIN; SHORT CHAIN FATTY ACID; SIRTUIN; SIRTUIN 1; SIRTUIN 2; SIRTUIN 3; SIRTUIN 6; SUPPRESSOR OF CYTOKINE SIGNALING 3; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; VANCOMYCIN;

ABDOMINAL PAIN; ACTINOBACTERIA; ANTIBIOTIC THERAPY; BACTERIAL ENDOCARDITIS; BACTEROIDETES; BLOATING; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE PREDISPOSITION; ENTERITIS; FIRMICUTES; GASTROESOPHAGEAL REFLUX; GLYCEMIC CONTROL; HUMAN; INFLAMMATION; INSULIN RESISTANCE; INTESTINE FLORA; INTESTINE INNERVATION; IRRITABLE COLON; LIPID DIET; LOW DRUG DOSE; NONHUMAN; OBESITY; PATHOGENESIS; REVIEW; SIDE EFFECT; WEIGHT GAIN; WEIGHT REDUCTION; ANIMAL; GASTROINTESTINAL TRACT; INNERVATION; METABOLISM; METAGENOME; MICROBIOLOGY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; ENTERIC NERVOUS SYSTEM; GASTROINTESTINAL TRACT; HUMANS; INFLAMMATION; METAGENOME; OBESITY; SIRTUINS;

EID: 82055164131     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-9-202     Document Type: Review

References (128)

1. Matsushita Y, Yoshiike F, Yoshita K, Takimoto H. Trends in childhood obesity in Japan over the last 25 years from the national nutrition survey. Obesity Res 2004, 12:205-214.
2. Sasai H, Sairenchi T, Hiroyasu I, Irie F, Otaka E, Tanaka K, Ota H, Muto T. Relationship between obesity and incident diabetes in middle-aged and older Japanese adults: The Ibaraki prefectural health study. Mayo Clin Proc 2010, 85:36-40.
3. Field AE, Coakley EH, Must A, Spadano JL, Laird N, Dietz WH, Rimm E, Colditz GA. Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Arch Intern Med 2001, 161:1581-1586.
4. Delgado-Aros S, Locke GR, Camilleri M, Talley NJ, Fett S, Zinsmeister AR, Melton LJ. Obesity is associated with increased risk of gastrointestinal symptoms: a population-based study. Am J Gastroenterol 2004, 99:1801-1806.
5. Snoek SA, Verstege MI, Boeckxstaens GE, van den Wijngaard RM, de Jonge WJ. The enteric nervous system as a regulator of intestinal epithelial barrier function in health and disease. Expert Rev Gastroenterol Hepatol 2010, 4:637-651.
6. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006, 444:860-867.
7. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 2001, 280:E745-E751.
8. Syrenicz A, Garanty-Bogachka B, Syrenicz M, Gebala A, Walczak M. Low-grade systemic inflammation and the risk of type 2 diabetes in obese children and adolescents. Neuro Endocrinol Lett 2006, 27:453-458.
9. Panagiotakos DB, Pitsavos C, Yannakoulia M, Chrysohoou C, Stefanadis C. The implication of obesity and central fat on markers of chronic inflammation: The ATTICA study. Atherosclerosis 2005, 183:308-315.
10. Viser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Low-grade systemic inflammation in overweight children. Pediatrics 2001, 107:E13.
11. Brake DK, Smith EO, Mersmann H, Smith CW, Robker RL. ICAM-1 expression in adipose tissue: effects of diet-induced obesity in mice. Am J Physiol Cell Physiol 2006, 291:C1232-1239.
12. Kim SJ, Choi Y, Choi YH, Park T. Obesity activates toll-like receptor-mediated proinflammatory signaling cascades in the adipose tissue of mice. J Nutr Biochem 2011,
13. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003, 1123:1821-1830.
14. DiBaise JK, Zhang H, Crowell MD, Krajmalnik-Brown R, Decker GA, Rittmann BE. Gut microbiota and its possible relationship with obesity. Mayo Clin Proc 2008, 83:460-469.
15. Conterno L FF, Viola R, Tuohy KM. Obesity and the gut microbiota: does up-regulating colonic fermentation protect against obesity and metabolic disease?. Genes Nutr 2011, 6:241-260.
16. Bäckhed F, Ding H, Wang T, Hooper LV, Koh GY, Nagy A, Semenkovich CF, Gordon JI. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci 2004, 101:15718-15723.
17. de La Serre CB, Ellis CL, Lee J, Hartman AL, Rutledge JC, Raybould HE. Propensity to high-fat diet-induced obesity in rats is associated with changes in the gut microbiota and gut inflammation. Am J Physiol Gastrointest Liver Physiol 2010, 299:G440-448.
18. Cani PD, Neyrinck AM, Fava F, Knauf C, Burcelin RG, Tuohy KM, Gibson GR, Delzenne NM. Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia 2007, 50:2374-2383.
19. Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM, Burcelin R. Changes in gut microbiota could control endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 2008, 57:1470-1481.
20. Cani PD, Delzenne NM, Amar J, Burcelin R. Role of gut microflora in the development of obesity and insulin resistance following high-fat diet feeding. Pathol Biol (Paris) 2008, 56:305-309.
21. Cani PD, Possemiers S, Van de Wiele T, Guiot Y, Everard A, Rottier O, Geurts L, Naslain D, Neyrinck A, Lambert DM, et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 2009, 58:1091-1103.
22. Griffiths EA, Duffy LC, Schanbacher FL, Qiao H, Dryja D, Leavens A, Rossman J, Rich G, Dirienzo D, Ogra PL. In vivo effects of bifidobacteria and lactoferrin on gut endotoxin concentration and mucosal immunity in Balb/c mice. Dig Dis Sci 2004, 49:579-589.
23. Wang Z, Xiao G, Yao Y, Guo S, Lu K, Sheng Z. The role of bifidobacteria in gut barrier function after thermal injury in rats. J Trauma 2006, 61:650-657.
24. Brun P, Castagliuolo I, Di Leo V, Buda A, Pinzani M, Palu G, Martines D. Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol 2007, 292:G518-G525.
25. Scarpellini E, Campanale M, Leone D, Purchiaroni F, Vitale G, Lauritano EC, Gasbarrini A. Gut microbiota and obesity. Intern Emerg Med 2010, 5(Suppl 1):S53-56.
26. Santacruz A, Marcos A, Wärnberg J, Martí A, Martin-Matillas M, Campoy C, Moreno LA, Veiga O, Redondo-Figuero C, Garagorri JM, et al. Interplay between weight loss and gut microbiota composition in overweight adolescents. Obesity 2009, 17:1906-1915.
27. Chaudhri O, Wynne K, Bloom SR. Can gut hormones control appetite and prevent obesity?. Daibetes Care 2008, 31(Suppl 2):S284-S289.
28. Furet JP, Kong LC, Tap J, Poitou C, Basdevant A, Bouillot JL, Mariat D, Corthier G, Doré J, Henegar C, et al. Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss: links with metabolic and low-grade inflammation. Diabetes 2010, 59:3049-3057.
29. Kelly G. A review of the sirtuin system, its clinical implications, and the potential role of dietary activators like resveratrol: part 2. Alt Med Rev 2010, 15:313-338.
30. Schug TT, Li X. Sirtuin 1 in lipid metabolism and obesity. Ann Med 2011,
31. Greiner T, Backhed F. Effects of the gut microbiota on obesity and glucose homeostasis. Trends Endocrinol Metab 2011,
32. Hildebrandt MA, Hoffmann C, Sherrill-Mix SA, Keilbaugh SA, Hamady M, Chen YY, Knight R, Ahima RS, Bushman F, Wu GD. High-fat diet determines the composition of the murine gut microbiome independently of obesity. Gastroenterology 2009, 137:1716-1724.
33. Backhed F. Changes in intestinal microflora in obesity: cause or consequence?. J Pediatr Gastroenterol Nutr 2009, 48(Suppl 2):S56-S57.
34. Turnbaugh PJ, Bäckhed F, Fulton L, Gordon JI. Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome. Cell Host Microbe 2008, 3:213-223.
35. Damaskos D, Kolios G. Probiotics and prebiotics in inflammatory bowel disease: microflora "on the scope". Br J Clin Pharmacol 2008, 65:453-467.
36. Bäckhed F, Manchester JK, Semenkovich CF, Gordon JI. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci 2007, 104:979-984.
37. Ley RE, Backhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI. Obesity alters gut microbial ecology. Proc Natl Acad Sci 2005, 102:11070-11075.
38. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006, 444:1027-1031.
39. Bjursell M, Admyre T, Goransson M, Marley AE, Smith DM, Oscarsson J, Bohlooly-Y M. Improved glucose control and reduced body fat mass in free fatty acid recepto 2-deficient mice fed a high-fat diet. Am J Physiol Endocrinol Metab 2011, 300:E211-220.
40. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature 2006, 444:1022-1023.
41. Zhang H, DiBaise JK, Zuccolo A, Kudrna D, Braidotti M, Yu Y, Parameswaran P, Crowell MD, Wing R, Rittmann BE, et al. Human gut microbiota in obesity and after gastric bypass. Proc Natl Acad Sci USA 2009, 106:2365-2370.
42. Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley RE, Sogin ML, Jones WJ, Roe BA, Affourtit JP, et al. A core gut microbiome in obese and lean twins. Nature 2009, 457:480-484.
43. Kalliomaki M, Collado MC, Salminen S, Isolauri E. Early differences in fecal microbiota composition in children may predict overweight. Am J Clin Nutr 2008, 87:534-538.
44. Collado MC IE, Laitinen K, Salminen S. Distinct composition of gut microbiota during pregnancy in overweight and normal-weight women. Am J Clin Nutr 2008, 88:894-899.
45. Wu X MC, Han L, Nawaz M, Gao F, Zhang S, Yu P, et al. Molecular characterisation of the faecal microbiota in patients with type II diabetes. Curr Microbiol 2010, 61:69-78.
46. Lupp C, Robertson ML, Wickham ME, Sekirov I, Champion OL, Gaynor EC, Finlay BB. Host-mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of Enterobacteriaceae. Cell Host Microbe 2007, 2:119-129.
47. Frost WJAJ. Antibiotics and animal production. Microbiology of Animals and Animal Products 1991, 181-194. New York: Elsevier, JB W.
48. Lin J. Effect of antibiotic growth promoters on intestinal microbiota in food animals: a novel model for studying the relationship between gut microbiota and human obesity?. Front Microbiol 2011, 2:53.
49. Thuny F R, Casalta JP, Angelakis E, Habib G, Raoult D. Vancomycin treatment of infective endocarditis is linked with recently acquired obesity. PLOS One 2010, 5:e9074.
50. Membrez M, Blancher F, Jaquet M, Bibiloni R, Cani PD, Burcelin RG, Corthesy I, Macé K, Chou CJ. Gut microbiota modulation with norfloxacin and ampicillin enhances glucose tolerance in mice. FASEB 2008, 22:2416-2426.
51. Koo HL, HL D. Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases. Curr Opin Gastroenterol 2010, 26:17-25.
52. Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, Mareya SM, Shaw AL, Bortey E, Forbes WP. Rifaximin therapy for patients with irritable bowel syndrome without constipation. NEJM 2011, 364:22-32.
53. Fain J. Release of inflammatory mediators by human adipose tissue is enhanced in obesity and primarily by the nonfat cells: A review. Mediators Inflamm 2010,
54. Ding S, Chi MM, Scull BP, Rigby R, Schwerbrock NM, Magness S, Jobin C, Lund PK. High-fat diet: bacteria interactions promote intestinal inflammation which precedes and correlates with obesity and insulin resistance in mouse. PLOS ONE 2010, 5:e12191.
55. Erridge C, Attina T, Spickett CM, Webb DJ. A high-fat meal induces low-grade endotoxemia: evidence of a novel mechanism of postprandial inflammation. Am J Clin Nutr 2007, 86:1286-1292.
56. Ghanim H, Abuaysheh S, Sia CL, Korzeniewski K, Chaudhuri A, Fernandez-Real J, Dandona P. Increase in plasma endotoxin concentrations and the expression of toll-like receptors and suppressor of cytokine signling-3 in mononuclear cells after a high-fat, high-carbohydrate meal. Diabetes Care 2009, 32:2281-2287.
57. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, Neyrinck AM, Fava F, Tuohy KM, Chabo C, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007, 56:1761-1772.
58. Anderson PD, Mehta NN, Wolfe ML, Hinkle CC, Pruscino L, Comiskey LL, Tabita-Martinez J, Sellers KF, Rickels MR, Ahima RS, et al. Innate immunity modulates adipokines in humans. J Clin Endocrinol Metab 2007, 92:2272-2279.
59. Vijay-Kumar M, Aitken JD, Carvalho FA, Cullender TC, Mwangi S, Srinivasan S, Sitaraman SV, Knight R, Ley RE, Gewirtz AT. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science 2010, 328:228-231.
60. Katz KD, Hollander D, Vadheim CM, McElree C, Delahunty T, Dadufalza VD, Krugliak P, Rotter JI. Intestinal permeability in patients with Crohn's disease and their healthy relatives. Gastroenterology 1989, 97(4):927-931.
61. Gribar SC, Richardson WM, Sodhi CP, Hackam DJ. No longer an innocent bystander: epithelial toll-like receptor signaling in the development of mucosal inflammation. Mol Med 2008, 14(9-10):645-659.
62. Bruewer M, Luegering A, Kucharzik T, Parkos CA, Madara JL, Hopkins AM, Nusrat A. Proinflammatory cytokines disrupt epithelial barrier function by apoptosis independent mechanisms. J Immunol 2003, 171:6164-6172.
63. Ohland CL, Macnaughton WK. Probiotic bacteria and intestinal epithelial barrier function. Am J Physiol Gastrointest Liver Physiol 298(6):G807-819.
64. Bixquert Jimenez M. Treatment of irritable bowel syndrome with probiotics. An etiopathogenic approach at last?. Rev Esp Enferm Dig 2009, 101(8):553-564.
65. Guyonnet D, Chassany O, Ducrotte P, Picard C, Mouret M, Mercier CH, Matuchansky C. Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. Aliment Pharmacol Ther 2007, 26:475-486.
66. Kondo S, Xiao J-Z, Satoh T, Odamaki T, Takahashi S, Sugahara H, Yaeshima T, Iwatsuki K, Kamei A, Abe K. Antiobesity effects of Bifidobacterium breve strain B-3 supplementation in a mouse model with high-fat diet-induced obesity. Biosci, Biotechnol, Biochem 2010, 74:1656-1661.
67. Kunze WA MY, Wang B, Huizinga JD, Ma X, Forsythe P, Bienenstock J. Lactobacillus reuteri enhances excitability of colonic AH neurons by inhibiting calcium-dependent potassium channel opening. J Cell Mol Med 2009, 13:2261-2270.
68. Ma X MY, Wang B, Huizinga JD, Bienenstock J, Kunze W. Lactobacillus reuteri ingestion prevents hyperexcitability of colonic DRG neurons induced by noxious stimuli. Am J Physiol Gastrointest Liver Physiol 2009, 296:G868-875.
69. McKeman DP FP, Dinan TG, Cryan JF. The probiotic Bifidobacterium infantis 35624 displays visceral antinociceptive effects in the rat. Neurogastroenterol Motil 2010, 22:1029-1035.
70. Bar F VKH, Roblick U, Bruch HP et A. Cell-free supernatants of Escherichia coli Nissle 1917 modulate human colonic motility; evidence from an in vitro organ bath study. Neurogastroenterol Motil 2009, 21:559-566.
71. Wang B MY, Diorio C, Wang L, Huizinga JD, Bienenstock J, Kunze W. Lactobacillus reuteri ingestion and IK(Ca) channel blockade have similar effects on rat colon motility and myenteric neurons. Neurogastroenterol Motil 2010, 22:98-107.
72. Levy RL, Linde JA, Feld KA, Crowell MD, Jeffery RW. The association of gastrointestinal symptoms with weight, diet, and exercise in weight-loss program participants. Clin Gastroenterol Hepatol 2005, 3:992-996.
73. Talley NJ, Howell S, Poulton R. Obesity and chronic gastrointestinal tract symptoms in young adults: a birth cohort study. Am J Gastroenterol 2004, 99:1807-1814.
74. Verdich C, Madsen JL, Toubro S, Buemann B, Holst JJ, Astrup A. Effect of obesity and major weight reduction on gastric emptying. Int J Obes Relat Metab Disord 2000, 24:899-905.
75. Ashburn DD, Reed MJ. Gastrointestinal system and obesity. Crit Care Clin 2010, 26:625-627.
76. Moayyedi P. The epidemiology of obesity and gastrointestinal and other diseases: an overview. Dig Dis Sci 2008, 53:2293-2299.
77. Choi CW, Kim GH, Song CS, Wang SG, Lee BJ IH, Kang DH, Song GA. Is obesity associated with gastropharngeal reflux disease?. World J Gastroenterl 2008, 14:265-271.
78. Dore MP, Maragkoudakis E, Fraley K, Pedroni A, Tadeu V, Realdi G, Graham DY, Delitala G, Malaty HM. Diet, lifestyle, and gender in gastro-esophageal reflux disease. Dig Dis Sci 2008, 53:2027-2032.
79. Dickman R, Feroze H, Fass R. Gastroesophageal reflux disease and irritable bowel syndrome: a common overlap syndrome. Curr Gastroenterol Rep 2006, 8:261-265.
80. Nocon M, Labenz J, Jaspersen D, Meyer-Sabellek W, Stolte M, Lind T, Malfertheiner P, Willich SN. Association of body mass index with heartburn, regurgitation and esophagitis: results of the progression of gastroesophageal reflux disease study. J Gastroenterol Hepatol 2007, 22:1728-1731.
81. Schmulson M, Pulido D, Escobar C, Farfan-Labone B, Lopez-Alvarenga JC. Heartburn and other related symptoms are independent of body mass index in irritable bowel syndrome. Rev Exp Enferm Dig (Madrid) 2010, 102:229-233.
82. John BJ, Irukulla S, Abulafi AM, Kumar D, Mendall MA. Systematic review: adipose tissue, obesity and gastrointestinal diseases. Aliment Pharmacol Ther 2006, 23:1511-1523.
83. Bassett JK, Severi G, English DR, Bagietto L, Krishnan K, Hopper JL, Giles GG. Body size, weight change, and risk of colon cancer. Cancer Epediemiol Biomarkers Prev 2010, 19:2978-2986.
84. Stachowicz M, Mazurek U, Nowakowska-Zajdel E, Niedworok E, Fatyga E, Muc-Wierzgon M. Leptin and its receptors in obese patients with colorectal cancer. J Biol Regul Homeost Agents 2010, 24:287-295.
85. Catalán V, Gómez-Ambrosi J, Rodríguez A, Ramírez B, Silva C, Rotellar F, Hernández-Lizoain JL, Baixauli J, Valentí V, Pardo F, et al. Up-regulation of the novel proinflammatory adipokines lipocalin-2, chitinase-3 like 1 and osteopontin as well as angiogenic-related factors in visceral adipose tissue of patients with colon cancer. J Nutr Biochem 2010,
86. Padidar S, Farquharson AJ, Williams LM, Kelaiditi E, N H, Arthur JR, Drew JE. Leptin upregulates pro-inflammatory cytokines in discrete cells within mouse colon. J Cell Physiol 2010,
87. Pendyala S, Neff LM, Suarez-Farinas M, Holt PR. Diet-induced weight loss reduces colorectal inflammation: implications for colorectal carcinogenesis. Am J Clin Nutr 2010,
88. Bonilla S, Wang D, Saps M. Obesity predicts persistence of pain in children with functional gastrointestinal disorders. Int J Obes (Lond) 2010,
89. Venkatasubramani N, Telega G, Werlin SL. Obesity in pediatric celiac disease. J Pediatr Gastroenterol Nutr 2010, 51:295-297.
90. Furness J. The enteric nervous system: normal functions and enteric neuropathies. Neurogastroenterol Motil 2008, 20(Suppl 1):32-38.
91. Mawe GM SD, Sharkey KA. Plasticity of enteric nerve functions in the inflamed and postinflamed gut. Neurogastroenterol Motil 2009, 21:481-491.
92. Lakhan SE, Kirchgessner A. Neuroinflammation in inflammatory bowel disease. J Neuroinflammation 2010, 7:37.
93. Geboes K, Collins S. Structural abnormalities of the nervous system in Crohn's disease and ulcerative colitis. Neurogastroenterol Motil 1998, 10:189-202.
94. Bernardini N, Segnani C, Ippolito C, De Griogio R, Colucci R, Faussone-Pellegrini MS, Chiarugi M, Campani D, Castagna M, Mattii L, et al. Immunohistochemical analysis of myenteric ganglia and interstitial cells of Cajal in ulcerative colitis. J Cell Mol Med 2011,
95. De Giorgio R, Camilleri M. Human enteric neuropathies: morphology and molecular pathology. Neurogastroenterol Motil 2004, 16(5):515-531.
96. Tornblom H, Lindberg G, Nyberg B, Veress B. Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome. Gastroenterology 2002, 123(6):1972-1979.
97. Hoffman JM MN, Sharkey KA, Mawe GM. The relationship between inflammation-induced neuronal excitability and disrupted motor activity in the guinea pig distal colon. Neurogastroenterol Motil 2011, 23:673.
98. Dunlop SP, Jenkins D, Spiller RC. Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome. Am J Gastroenterol 2003, 98(7):1578-1583.
99. Isgar B, Harman M, Kaye MD, Whorwell PJ. Symptoms of irritable bowel syndrome in ulcerative colitis in remission. Gut 1983, 24(3):190-192.
100. Hyland NP, Rybicka JM, Ho W, Pittman QJ, Macnaughton WK, Sharkey KA. Adaptation of intestinal secretomotor function and nutrient absorption in response to diet-induced obesity. Neurogastroenterol Motil 2010, 22:602-e171.
101. Sullivan A, Nord CE, Evengard B. Effect of supplement with lactic-acid producing bacteria on fatigue and physical activity in patients with chronic fatigue syndrome. Nutr J 2009, 8:4.
102. Mostoslavsky R, Chua KF, Lombard DB, Pang WW, Fischer MR, Gellon L LP, Mostoslavsky G, Franco S, Murphy MM, Mills KD, et al. Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. Cell 2006, 124:315-329.
103. Xiao C, Kim HS, Lahusen T, Wang RH, Xu X, Gavrilova O, Jou W, Gius D, Deng CX. SIRT6 deficiency results in severe hypoglycemia by enhancing both basal and insulin-stimulated glucose uptake in mice. J Biol Chem 2010, 285:36776-36784.
104. Kanfi Y, Peshti V, Gil R, Naiman S, Nahum L, Levin E, Kronfeld-Schor N, Cohen HY. SIRT6 protects against pathological damage caused by diet-induced obesity. Aging Cell 2010, 9:162-173.
105. Schwer B, Schumacher B, Lombard DB, Xiao C, Kurtev MV, Gao J, Schneider JI, Chai H, Bronson RT, Tsai LH, et al. Neural sirtuin 6 (Sirt6) ablation attenuates somatic growth and causes obesity. PNAS 2010, 107:21790-21794.
106. Kendrick AA, Choudhury M, Rahman SM, McCurdy CE, Friederich M, Van Hove JL, Watson PA, Birdsey N, Bao J, Gius D, et al. Fatty liver is associated with reduced SIRT3 activity and mitochondrial protein hyperacetylation. Biochem J 2011, 433:505-514.
107. Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG, Zipkin RE, Chung P, Kisielewski A, Zhang LL, et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003, 425:191-196.
108. Wood JG, Rogina B, Lavu S, Howitz K, Helfand SL, Tatar M, Sinclair D. Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature 2004, 430:686-689.
109. Kim S, Jin Y, Choi Y, Park T. Resveratrol exerts anti-obesity effects via mechanisms involving down-regulation of adipogenic and inflammatory processes in mice. Biochem Pharmacol 2011,
110. Qiao I, Shao J. Sirt1 regulates adiponectin gene expression through Foxo1-C/EBPalpha transcriptional complex. J Biol Chem 2006, 281:39915-39924.
111. Picard F, Kurtev M, Chung N, Topark-Ngarm A, Senawong T, Machado De Oliveira R, Leid M, McBurney MW, Guarente L. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature 2004, 429:771-776.
112. Pedersen SB, Olholm J, Paulsen SK, Bennetzen MF, Richelsen B. Low Sirt1 expression, which is upregulated by fasting, in human adipose tissue from obese women. Int J Obes (Lond) 2008, 32:1250-1255.
113. Peeters AV, Beckers S, Verrijken A, Mertens I, Roevens P, Peeters PJ, Van Hul W, Van Gaal LF. Association of SIRT1 gene variation with visceral obesity. Hum Genet 2008, 124:431-436.
114. Zillikens MC, van Meurs JBJ, Rivadeneira F, Amin N, Hofman A, Oostra B, Sijbrands EJ, Witteman JC, Pols HA, van Duijn CM, et al. SIRT1 genetic variation is related to BMI and risk of obesity. Diabetes 2009, 58:2828-2834.
115. Zhu J, Yong W, Wu X, Yu Y, Lv J, Liu C, Mao X, Zhu Y, Xu K, Han X, et al. Anti-inflammatory effect of resveratrol on TNF-a-induced MCP-1 expression in adipocytes. Biochem Biophys Res Commun 2008, 369:471-477.
116. Pfluger PT, Herranz D, Velasco-Miguel S, Serrano M, Tschop MH. Sirt1 protects against high-fat diet-induced metabolic damage. Proc Natl Acad Sci 2008, 105:9793-9798.
117. Fischer-Posovszky P, Kukulus V, Tews D, Unterkircher T, Debatin KM, Fulda S, Wabitsch M. Resveratrol regulates human adipocyte number and function in a Sirt1-dependent manner. Am J Clin Nutr 2010, 92:5-15.
118. Yoshizaki T, Milne JC, Imamura T, Schenk S, Sonoda N, Babendure JL, Lu JC, Smith JJ, Jirousek MR, Olefsky JM. Sirt1 exerts anti-inflammatory effect and improves insulin sensitivity in adipocytes. Mol Cell Biol 2009, 29:1363-1374.
119. Ramadori G, Lee CE, Bookout AL, Lee S, Williams KW, Anderson J, Elmquist JK, Coppari R. Brain SIRT1: anatomical distribution and regulation by energy availability. J Neurosci 2008, 28:9989-9996.
120. Cakir I, Perello M, Lansari O, Messier NJ, Vaslet CA, Nillni EA. Hypothalmaic SIRT1 regulates food intake in a rodent model system. PLOS ONE 2009, 4:e8322.
121. Ramadori G, Fujikawa T, Fukuda M, Anderson J, Morgan DA, Mostoslavsky R, Stuart RC, Perello M, Vianna CR, Nillni EA, et al. SIRT1 deacetylase in POMC neurons is required for homeostatic defenses against diet-induced obesity. Cell Metab 2010, 12.
122. Bereswill S, Muñoz M, Fischer A, Plicket R, Haag LM, Otto B, Kühl AA, Loddenkemper C, Göbel UB, Heimesaat MM. Anti-inflammatory effects of resveratrol, curcumin and simvastatin in acute small intestinal inflammation. PLOS One 2010, 5:e15099.
123. Hofseth LJ, Singh UP, Singh NP, Nagarkatti M, Nagarkatti PS. Taming the beast within: resveratrol suppresses colitis and prevents colon cancer. Aging 2010, 2:183-184.
124. Larrosa M, Yanez-Gascon MJ, Selma MV, Gonzalez-Sarrias A, Toti S, Ceron JJ, Tomas-Bareran F, Dolara P, JC E. Effect of low dose of dietary resveratrol on colon microbiota, inflammation and tissue damage in a DSS-induced colitis rat model. J Agric Food Chem 2009, 57:2211-2220.
125. Cani PD, Delzenne NM. Involvement of the gut microbiota in the development of low grade inflammation associated with obesity: focus on this neglected partner. Acta Gastroenterol Belg 2010, 73:267-269.
126. Vanamala J, Tarver CC, Murano PS. Obesity-enhanced colon cancer: functional food compounds and their mechanisms of action. Curr Cancer Drug Targets 2008, 8:611-633.
127. Bernard CE, Gibbons SJ, Gomez-Pinilla PJ, Lurken MS, Schmalz PF, Roeder JL, Linden D, Cima RR, Dozois EJ, Larson DW, et al. Effect of age on the enteric nervous system of the human colon. Neurogastroenterol Motil 2009, 21:746-747.
128. Liu M, Kirchgessner AL. Agonist- and reflex-evoked internalization of metabotropic glutamate receptor 5 in enteric neurons. J Neurosci 2000, 20:3200-3205.